Cargando…

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis

In this study we analyzed the concentration of lipoprotein(a) (Lp(a)), PCSK9-Lp(a) complexes and the circulating monocyte subsets in coronary atherosclerosis. For this study, 257 patients with coronary atherosclerosis and 68 patients without stenotic atherosclerosis in the coronary, carotid and lowe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filatova, Anastasiia Yu., Afanasieva, Olga I., Arefieva, Tatiana I., Potekhina, Alexandra V., Tyurina, Alexandra V., Klesareva, Elena A., Razova, Oksana A., Ezhov, Marat V., Pokrovsky, Sergey N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381556/ https://www.ncbi.nlm.nih.gov/pubmed/37511689 http://dx.doi.org/10.3390/jpm13071077

Ejemplares similares

The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis
por: Afanasieva, Olga I., et al.
Publicado: (2021)

Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease
por: Afanasieva, Olga I., et al.
Publicado: (2022)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease
por: Afanasieva, Olga I., et al.
Publicado: (2023)

Low Molecular Weight Apolipoprotein(a) Phenotype Rather Than Lipoprotein(a) Is Associated With Coronary Atherosclerosis and Myocardial Infarction
por: Afanasieva, Olga I., et al.
Publicado: (2022)

Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis
por: Chubykina, Uliana V., et al.
Publicado: (2022)

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease
por: Tmoyan, Narek A., et al.
Publicado: (2021)

Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis
por: Burdeynaya, Anna L., et al.
Publicado: (2023)

Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries
por: Ezhov, Marat V., et al.
Publicado: (2021)

Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction
por: Ovchinnikov, Artem, et al.
Publicado: (2023)

Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels
por: Ezhov, Marat, et al.
Publicado: (2019)

The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction
por: Ovchinnikov, A. G., et al.
Publicado: (2020)

Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types
por: Ilina, Larisa N., et al.
Publicado: (2022)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
por: Zhang, Xiang, et al.
Publicado: (2020)

The severity of internal carotid artery stenosis is associated with the circulating Th17 level
por: Filatova, A.Yu., et al.
Publicado: (2020)

Lp-PLA2 Inhibition—The Atherosclerosis Panacea?
por: Karakas, Mahir, et al.
Publicado: (2010)

The AAV-PCSK9 murine model of atherosclerosis and metabolic dysfunction
por: Keeter, William Coles, et al.
Publicado: (2022)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
por: Wong Chong, Emilie, et al.
Publicado: (2022)

CRP Is Transported by Monocytes and Monocyte-Derived Exosomes in the Blood of Patients with Coronary Artery Disease
por: Melnikov, Ivan, et al.
Publicado: (2020)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability
por: Enkhmaa, Byambaa, et al.
Publicado: (2020)

Trained Circulating Monocytes in Atherosclerosis: Ex Vivo Model Approach
por: Nikiforov, Nikita G., et al.
Publicado: (2019)

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
por: Seidah, Nabil G., et al.
Publicado: (2022)

PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system
por: Lee, Jounghyun H., et al.
Publicado: (2023)

Intermediate Monocytes and Circulating Endothelial Cells: Interplay with Severity of Atherosclerosis in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus
por: Kologrivova, Irina V., et al.
Publicado: (2023)

Mechanosensitivity of Cells and Its Role in the Regulation of Physiological Functions and the Implementation of Physiotherapeutic Effects (Review)
por: Potekhina, Yu.P., et al.
Publicado: (2020)

Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome
por: Ezhov, Marat V., et al.
Publicado: (2023)

New developments in atherosclerosis: clinical potential of PCSK9 inhibition
por: Giunzioni, Ilaria, et al.
Publicado: (2015)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
por: Punch, Emily, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
por: Ezhov, Marat V., et al.
Publicado: (2023)

A Cytofluorometric Study of Membrane Rafts in Human Monocyte Subsets in Atherosclerosis
por: Chelombitko, M. A., et al.
Publicado: (2014)

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
por: Wang, Yanan, et al.
Publicado: (2023)

Frequency of monocyte subsets is linked to the severity of atherosclerosis in patients with ischemic heart disease: A case-control study
por: Kologrivova, Irina, et al.
Publicado: (2020)

On the present and future role of Lp-PLA(2) in atherosclerosis-related cardiovascular risk prediction and management
por: Fras, Zlatko, et al.
Publicado: (2020)

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
por: Sun, Hua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_asrnokj1omn38nin47i6baku37